While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if ...
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives...
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted n...
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine...
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg)...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr....
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel ...
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive...
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non...
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.85 per share a year ago....
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant ( CRN 0 4894 ) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO June ...